%0 Journal Article
%T Invasive pulmonary aspergillosis among patients with severe community-acquired pneumonia and influenza in ICUs: a retrospective cohort study.
%A Lee WC
%A Chang CC
%A Ho MC
%A Lin CM
%A Leu SW
%A Lin CK
%A Fang YH
%A Huang SY
%A Lin YC
%A Chuang MC
%A Yang TM
%A Hung MS
%A Chou YL
%A Tsai YH
%A Hsieh MJ
%J Pneumonia (Nathan)
%V 16
%N 1
%D 2024 May 25
%M 38790032
暂无%R 10.1186/s41479-024-00129-9
%X <B>BACKGROUND: </B>The prevalence, clinical characteristics, and outcomes of invasive pulmonary aspergillosis in patients with severe community-acquired pneumonia (CAP) in intensive care units remain underestimated because of the lack of a disease-recognition scheme and the inadequacy of diagnostic tests.<BR><B>OBJECTIVE: </B>To identify the prevalence, risk factors, and outcomes of severe CAP complicated with invasive pulmonary aspergillosis (IPA) in intensive care units (ICUs).<BR><B>METHODS: </B>We conducted a retrospective cohort study including recruited 311 ICU-hospitalized patients with severe CAP without influenza or with influenza. Bronchoalveolar lavage fluid (BALF) samples were from all patients and subjected to mycological testing. Patients were categorized as having proven or probable Aspergillus infection using a modified form of the AspICU algorithm comprising clinical, radiological, and mycological criteria.<BR><B>RESULTS: </B>Of the 252 patients with severe CAP and 59 influenza patients evaluated, 24 met the diagnostic criteria for proven or probable Aspergillus infection in the CAP group and 9 patients in the influenza group, giving estimated prevalence values of 9.5% and 15.3%, respectively. COPD and the use of inhaled corticosteroids were independent risk factors for IPA. IPA in patients with severe CAP was significantly associated with the duration of mechanical support, the length of ICU stay, and the 28-day mortality.<BR><B>CONCLUSIONS: </B>An aggressive diagnostic approach for IPA patients with severe CAP and not only influenza or COVID-19 should be pursued. Further randomized controlled trials need to evaluate the timing, safety, and efficacy of antifungal therapy in reducing IPA incidence and improving clinical outcomes.